{"title":"Thyroid Cancer","description":null,"products":[{"product_id":"briganix-brigatinib-2","title":"Larotreni (Larotrectinib)","description":"Larotrectinib is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change. You might have larotrectinib for a solid cancer if: your cancer is locally advanced or advanced (metastatic) surgery to remove the cancer could cause severe health problems.\r\n\u003ch3\u003eSolid Tumors\u003c\/h3\u003e\r\nIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\r\n\r\n100 mg PO BID\r\n\r\nContinue until disease progression or until unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eBody Surface Area (BSA) ≥1 m2\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946396715,"sku":"RL1420230901296990","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1444.png?v=1787022074"},{"product_id":"lyvioni-lenvatinib-4","title":"Lyvioni-4 (Lenvatinib)","description":"Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\r\n\r\n24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\r\n\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_everolimus\"\u003eCombination therapy with everolimus\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\r\n \t\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_pembrolizumab\"\u003eCombination therapy with pembrolizumab\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\r\n \t\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\r\n\u003ch4\u003e\u003cspan id=\"Dose_based_on_actual_body_weight\"\u003eDose based on actual body weight\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\u003cspan id=\"Endometrial_Cancer\"\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\r\n\r\n20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\r\nRefer to pembrolizumab prescribing information for recommended dosing information\r\n\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"DTC_dose_reductions\"\u003eDTC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"RCC_or_endometrial_carcinoma_dose_reductions\"\u003eRCC or endometrial carcinoma dose reductions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_everolimus_in_RCC\"\u003eDose modification of everolimus in RCC\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_pembrolizumab_in_endometrial_carcinoma\"\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"HCC_dose_reductions\"\u003eHCC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"First_occurrence\"\u003eFirst occurrence\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Second_occurrence\"\u003eSecond occurrence\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Third_occurrence\"\u003eThird occurrence\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hypertension\"\u003eHypertension\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Cardiac_dysfunction\"\u003eCardiac dysfunction\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Arterial_thrombotic_event\"\u003eArterial thrombotic event\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Proteinuria\"\u003eProteinuria\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\r\n \t\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"GI_toxicity\"\u003eGI toxicity\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_failure_or_impairment\"\u003eRenal failure or impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Reversible_posterior_leukoencephalopathy_syndrome_RPLS\"\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Severe_CrCl_30_mLmin\"\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Severe_Child-Pugh_C\"\u003eSevere (Child-Pugh C)\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946658859,"sku":"RL142023090152","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663298393-8916879d1cfb675.png?v=1787022078"},{"product_id":"lenvima-lenvatinib-4mg","title":"Lyvioni-10 (Lenvatinib)","description":"Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003eDifferentiated Thyroid Cancer\u003c\/h3\u003e\r\nIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\r\n\r\n24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\r\n\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\r\n\u003ch4\u003eCombination therapy with everolimus\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\r\n \t\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCombination therapy with pembrolizumab\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\r\n \t\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHepatocellular Carcinoma\u003c\/h3\u003e\r\nIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\r\n\u003ch4\u003eDose based on actual body weight\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eEndometrial Cancer\u003c\/h3\u003e\r\nIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\r\n\r\n20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\r\nRefer to pembrolizumab prescribing information for recommended dosing information\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDTC dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRCC or endometrial carcinoma dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eDose modification of everolimus in RCC\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHCC dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eFirst occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSecond occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eThird occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHypertension\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCardiac dysfunction\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eArterial thrombotic event\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatoxicity\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eProteinuria\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\r\n \t\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eGI toxicity\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRenal failure or impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eQTc prolongation\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRenal impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSevere (Child-Pugh C)\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946953771,"sku":"RL1420230901138","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1767.jpg?v=1787022083"},{"product_id":"aentrekentrectinib-100mg","title":"Aentrek 100 (entrectinib)","description":"\u003cdiv class=\"collapse-more\"\u003e\r\n\u003ch3\u003e\u003cspan id=\"Non-small_Cell_Lung_Cancer\"\u003eNon-small Cell Lung Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003c\/div\u003e\r\nIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are ROS1-positive\r\n\r\n600 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Neurotrophic_Tyrosine_Receptor_Kinase_Gene_Fusion_Solid_Tumors\"\u003eNeurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumors\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and progressed following treatment or have no satisfactory alternative therapy\r\n\r\n600 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 400 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 200 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003ePermanently discontinue if toxicities persist or recur following 2 dose reductions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Congestive_heart_failure\"\u003eCongestive heart failure\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 2 or 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Central_nervous_system_effects\"\u003eCentral nervous system effects\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIntolerable Grade 2: Withhold until recovered to Grade ≤1; resume at reduced dose, as clinically appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduced dose;\u003c\/li\u003e\r\n \t\u003cli\u003eIf resolution occurs within 4 weeks, resume at same dose\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reaction persists after 4 weeks, permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eFor recurrent Grade 3 events that resolve within 4 weeks, resume at a reduced dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Grade_4\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduce dose;\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reaction does not resolve within 4 weeks or Grade 4 events recurs, permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Elevated_ALT_or_AST\"\u003eElevated ALT or AST\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eALT or AST \u0026gt;3x ULN with concurrent total bilirubin \u0026gt;1.5x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hyperuricemia\"\u003eHyperuricemia\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eSymptomatic or Grade 4: Initiate urate-lowering therapy; withhold until improvement of signs or symptoms; resume at same or reduced dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"QTc_500_ms\"\u003eQTc \u0026gt;500 ms\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until QTc interval recovers to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at same dose if causes of QT prolongation are identified and corrected\u003c\/li\u003e\r\n \t\u003cli\u003eResume at reduced dose if other causes of QT prolongation are not identified\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Life-threatening_arrhythmia\"\u003eLife-threatening arrhythmia\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTorsade de pointes; polymorphic ventricular tachycardia; signs\/symptoms of serious arrhythmia: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Vision_disorders\"\u003eVision disorders\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade ≥2: Withhold until improvement or stabilization; resume at same dose or reduced dose, as clinically appropriate\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Anemia_or_neutropenia\"\u003eAnemia or neutropenia\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until recovery to Grade≤2; resume at same or reduced dose, as clinically appropriate\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Other_clinically_relevant_adverse_reactions\"\u003eOther clinically relevant adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Grade_3_or_4\"\u003eGrade 3 or 4\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until adverse reaction resolves to Grade 1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at same or reduced dose if resolved within 4 weeks\u003c\/li\u003e\r\n \t\u003cli\u003ePermanently discontinue if adverse reaction does not resolve within 4 weeks or Grade 4 events recurs\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Coadministration_of_moderate_and_strong_CYP3A_inhibitors\"\u003eCoadministration of moderate and strong CYP3A inhibitors\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAvoid coadministration\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"If_coadministration_is_unavoidable_reduce_entrectinib_dose_as_follows\"\u003eIf coadministration is unavoidable, reduce entrectinib dose as follows:\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eModerate CYP3A Inhibitors: 200 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eStrong CYP3A Inhibitors: 100 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eAfter discontinuation of strong or moderate CYP3A inhibitor for 3-5 elimination half-lives, resume entrectinib dose taken prior to initiating the CYP3A inhibitor\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl 30 to \u0026lt;90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not studied\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild (total bilirubin ≤1.5x ULN): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eModerate-to-severe (total bilirubin \u0026gt;1.5x ULN): Not studied; consider risk-benefit profile prior to determining whether to administer therapy to patients with moderate to severe hepatic impairment; monitor for adverse reactions in patients with hepatic impairment more frequently; these patients may be at increased risk for adverse reactions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Patient_selection\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eNSCLC: Presence of ROS1 rearrangement\u003c\/li\u003e\r\n \t\u003cli\u003eLocally advanced or metastatic solid tumors: Presence of a NTRK gene fusion\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947019307,"sku":"RL1420230901535","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663296906-991924d4ac643fa.jpg?v=1787022083"},{"product_id":"aentrek","title":"Aentrek 200 (Entrectinib)","description":"\u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. It is also used to treat certain types of solid tumors in adults and children 12 years of age and older that cannot be treated by surgery or that has spread to other parts of the body and that worsened after treatment with other chemotherapy medications. \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.\r\n\r\n\u003cstrong\u003e\u003cu\u003eUsage\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib)at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.\r\n\r\nTake \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\r\n\r\nSwallow the capsules whole; do not open, chew, or crush them.\r\n\r\nIf you vomit immediately after you take \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), take another dose as soon as possible.\r\n\r\nAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\r\n\r\n\u003cstrong\u003e\u003cu\u003eOther uses for this medicine\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\r\n\r\n\u003cstrong\u003e\u003cu\u003eSpecial precautions should follow\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eBefore taking Aentrek(entrectinib)\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003etell your doctor and pharmacist if you are allergic to \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), any other medications, or any of the ingredients in \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) capsules. Ask your pharmacist for a list of the ingredients.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the following: aprepitant (Emend), certain antifungal medications such as fluconazole (Diflucan), itraconazole (Omel, Sporanox), or ketoconazole; certain medications for arrhythmias such as amiodarone (Nexterone, Pacerone), procainamide, quinidine (in Nuedexta), and sotalol (Betapace, Sorine, Sotylize); azithromycin (Zithromax); clarithromycin (Biaxin, in Prevpac); diltiazem (Cardizem, Tiazac, others); erythromycin (E.E.S., Erythrocin, others); enzalutamide (Xtandi); certain HIV medications such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, others), or saquinavir (Invirase); lithium (Lithobid); modafinil (Provigil); nefazodone; oxcarbazepine (Trileptal); phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus, Duetact, Oseni); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifater); oral steroids such as dexamethasone, methylprednisolone (Medrol), and prednisone (Rayos); and verapamil (Calan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor what herbal products you are taking.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor if you have or have ever had a nervous system condition, a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), a slow or irregular heartbeat, a heart attack, heart failure, or heart or liver disease.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for at least 5 weeks after your final dose. If you are a male, you and your partner should use birth control during your treatment with \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), call your doctor immediately. Entrectinib may harm the fetus.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor if you are breastfeeding. You should not breastfeed while you are taking \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) and for 7 days after the final dose.\u003c\/li\u003e\r\n \t\u003cli\u003eyou should know that \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib)may make cause dizziness or confusion. Do not drive a car or operate machinery until you know how this medication affects you.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003e\u003cu\u003eSpecial dietary instructions should I follow\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\nDo not eat grapefruit or drink grapefruit juice while taking this medication.\r\n\r\n\u003cstrong\u003eMissed or forget a dose\u003c\/strong\u003e\r\n\r\nIf you miss a dose by less than 12 hours, take the missed dose as soon as you remember it and then take the next dose at the scheduled time. However, if you miss a dose by more than 12 hours, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.\r\n\r\n\u003cstrong\u003e\u003cu\u003eSide effects can this medication cause?\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eAentrek(entrectinib) may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003etiredness\u003c\/li\u003e\r\n \t\u003cli\u003econstipation\u003c\/li\u003e\r\n \t\u003cli\u003ediarrhea\u003c\/li\u003e\r\n \t\u003cli\u003etaste changes\u003c\/li\u003e\r\n \t\u003cli\u003eheadache\u003c\/li\u003e\r\n \t\u003cli\u003ecough, fever, or other signs of infection\u003c\/li\u003e\r\n \t\u003cli\u003emuscle or joint pain\u003c\/li\u003e\r\n \t\u003cli\u003eback pain\u003c\/li\u003e\r\n \t\u003cli\u003eweight changes\u003c\/li\u003e\r\n \t\u003cli\u003erash\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty falling or staying asleep\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eSome side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003edifficulty with learning, memory, attention, or problem solving\u003c\/li\u003e\r\n \t\u003cli\u003emood changes such as anxiety, depression, confusion, or agitation\u003c\/li\u003e\r\n \t\u003cli\u003ebone pain or difficulty moving\u003c\/li\u003e\r\n \t\u003cli\u003evision problems or changes in vision\u003c\/li\u003e\r\n \t\u003cli\u003ejoint pain, stiffness, redness, or swelling\u003c\/li\u003e\r\n \t\u003cli\u003epain in upper right part of the stomach, yellowing of skin or eyes, loss of appetite, or bleeding or bruising easily\u003c\/li\u003e\r\n \t\u003cli\u003eshortness of breath; difficulty breathing when lying down; or swelling of the arms, legs, hands, or feet\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947052075,"sku":"RL14202309011545","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-08-2413.jpg?v=1787022085"},{"product_id":"cabonni-cabozantinib-80mg","title":"Cabonni 20 (Cabozantinib)","description":"\u003cdiv class=\"page-header\"\u003e\r\n\u003cdiv class=\"headers v2 lg\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv id=\"main-content\" role=\"main\"\u003e\r\n\u003ch2\u003eDescription\u003c\/h2\u003e\r\n\u003cstrong\u003eCabonni (Cabozantinib) \u003c\/strong\u003ecapsule is used to treat medullary thyroid cancer that has already spread to different parts of the body.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is used alone to treat advanced kidney cancer. It is also used in combination with nivolumab as first-line treatment for advanced kidney cancer.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is also used to treat a type of liver cancer, called hepatocellular carcinoma, in patients who have been previously treated with other medicines (eg, sorafenib).\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is also used to treat differentiated thyroid cancer that has already spread to different parts of the body, in patients who can no longer be treated with radioactive iodine or not able to receive radioactive iodine, and have been previously treated with other medicines (eg, VEGFR-targeted treatment) but did not work well.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body.\r\n\r\nThis medicine is available only with your doctor's prescription.\r\n\r\nThis product is available in the following dosage forms:\r\n\u003cul\u003e\r\n \t\u003cli\u003eCapsule\u003c\/li\u003e\r\n \t\u003cli\u003eTablet\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eBefore Using\u003c\/h2\u003e\r\nIn deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:\r\n\u003ch3\u003eAllergies\u003c\/h3\u003e\r\nTell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.\r\n\u003ch3\u003ePediatric\u003c\/h3\u003e\r\nAppropriate studies have not been performed on the relationship of age to the effects of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e in children younger than 12 years of age to treat differentiated thyroid cancer or in children to treat medullary thyroid cancer, liver cancer, and advanced kidney cancer. Safety and efficacy have not been established.\r\n\u003ch3\u003eGeriatric\u003c\/h3\u003e\r\nAppropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablets in the elderly.\r\n\r\nAppropriate studies have not been performed on the relationship of age to the effects of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e capsules in the geriatric population. However, no geriatric-specific problems have been documented to date.\r\n\u003ch3\u003eBreastfeeding\u003c\/h3\u003e\r\nThere are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.\r\n\u003ch3\u003eDrug Interactions\u003c\/h3\u003e\r\nAlthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.\r\n\r\nUsing this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.\r\n\u003cul\u003e\r\n \t\u003cli\u003eAbametapir\u003c\/li\u003e\r\n \t\u003cli\u003eApalutamide\u003c\/li\u003e\r\n \t\u003cli\u003eBoceprevir\u003c\/li\u003e\r\n \t\u003cli\u003eCarbamazepine\u003c\/li\u003e\r\n \t\u003cli\u003eCeritinib\u003c\/li\u003e\r\n \t\u003cli\u003eClarithromycin\u003c\/li\u003e\r\n \t\u003cli\u003eCobicistat\u003c\/li\u003e\r\n \t\u003cli\u003eConivaptan\u003c\/li\u003e\r\n \t\u003cli\u003eEnzalutamide\u003c\/li\u003e\r\n \t\u003cli\u003eFedratinib\u003c\/li\u003e\r\n \t\u003cli\u003eFexinidazole\u003c\/li\u003e\r\n \t\u003cli\u003eFosnetupitant\u003c\/li\u003e\r\n \t\u003cli\u003eFosphenytoin\u003c\/li\u003e\r\n \t\u003cli\u003eIdelalisib\u003c\/li\u003e\r\n \t\u003cli\u003eIndinavir\u003c\/li\u003e\r\n \t\u003cli\u003eItraconazole\u003c\/li\u003e\r\n \t\u003cli\u003eKetoconazole\u003c\/li\u003e\r\n \t\u003cli\u003eLopinavir\u003c\/li\u003e\r\n \t\u003cli\u003eLumacaftor\u003c\/li\u003e\r\n \t\u003cli\u003eMitotane\u003c\/li\u003e\r\n \t\u003cli\u003eNefazodone\u003c\/li\u003e\r\n \t\u003cli\u003eNelfinavir\u003c\/li\u003e\r\n \t\u003cli\u003eNetupitant\u003c\/li\u003e\r\n \t\u003cli\u003ePhenytoin\u003c\/li\u003e\r\n \t\u003cli\u003ePosaconazole\u003c\/li\u003e\r\n \t\u003cli\u003eRifampin\u003c\/li\u003e\r\n \t\u003cli\u003eRitonavir\u003c\/li\u003e\r\n \t\u003cli\u003eSaquinavir\u003c\/li\u003e\r\n \t\u003cli\u003eSt John's Wort\u003c\/li\u003e\r\n \t\u003cli\u003eTelaprevir\u003c\/li\u003e\r\n \t\u003cli\u003eTelithromycin\u003c\/li\u003e\r\n \t\u003cli\u003eVoriconazole\u003c\/li\u003e\r\n \t\u003cli\u003eWarfarin\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eOther Interactions\u003c\/h3\u003e\r\nCertain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.\r\n\r\nUsing this medicine with any of the following is usually not recommended, but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrapefruit Juice\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eOther Medical Problems\u003c\/h3\u003e\r\nThe presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:\r\n\u003cul\u003e\r\n \t\u003cli\u003eBleeding problems or\u003c\/li\u003e\r\n \t\u003cli\u003eBlood clots or\u003c\/li\u003e\r\n \t\u003cli\u003eHeart attack, acute or\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension (high blood pressure), uncontrolled or\u003c\/li\u003e\r\n \t\u003cli\u003eHypocalcemia (low calcium levels in the blood) or\u003c\/li\u003e\r\n \t\u003cli\u003eHypothyroidism or\u003c\/li\u003e\r\n \t\u003cli\u003eProteinuria (protein in the urine) or\u003c\/li\u003e\r\n \t\u003cli\u003eStomach fistula or perforation (a hole in the stomach) or\u003c\/li\u003e\r\n \t\u003cli\u003eStroke, recent—Use with caution. May make these conditions worse.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDental or tooth problems or\u003c\/li\u003e\r\n \t\u003cli\u003eDental procedures or surgery or\u003c\/li\u003e\r\n \t\u003cli\u003ePoor oral hygiene or\u003c\/li\u003e\r\n \t\u003cli\u003eTooth infection—May increase risk for severe jaw problems.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eHematemesis (vomiting of blood), recent or\u003c\/li\u003e\r\n \t\u003cli\u003eHemoptysis (coughing up blood), recent or\u003c\/li\u003e\r\n \t\u003cli\u003eHemorrhage (severe bleeding), recent history or\u003c\/li\u003e\r\n \t\u003cli\u003eMelena (black, tarry stools)—Should not be used in patients with these conditions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eLiver disease, mild or moderate—Use with caution. The effects may be increased because of slower removal of the medicine from the body.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eLiver disease, severe—Use is not recommended in patients with these conditions.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eProper Use\u003c\/h2\u003e\r\nMedicines used to treat cancer are very strong and can have many side effects. Before taking this medicine, make sure you understand all the risks and benefits. It is important for you to work closely with your doctor during your treatment.\r\n\r\nTake this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. To do so may increase the chance of unwanted effects.\r\n\r\nThis medicine comes with a patient information insert. Read and follow the instructions carefully. Ask your doctor if you have any questions.\r\n\r\n\u003cstrong\u003e\u003cspan style=\"color: #ff0000;\"\u003eDo not substitute Cabonni \u003cspan style=\"color: #000000;\"\u003etablets\u003c\/span\u003e with cabozantinib \u003cspan style=\"color: #0000ff;\"\u003ecapsules\u003c\/span\u003e. Do not substitute Cabonni \u003cspan style=\"color: #0000ff;\"\u003ecapsules\u003c\/span\u003e with cabozantinib \u003cspan style=\"color: #000000;\"\u003etablets.\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\r\n\r\nTake this medicine on an empty stomach. Do not eat for at least 2 hours before and at least 1 hour after taking this medicine.\r\n\r\nSwallow the medicine whole with a full glass (at least 8 ounces) of water. Do not crush, break, chew, or open the capsule or tablet.\r\n\r\nDo not eat grapefruit or drink grapefruit juice while you are using this medicine. Grapefruit and grapefruit juice may increase the amount of this medicine in the blood.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch3\u003eDosing\u003c\/h3\u003e\r\nThe dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.\r\n\r\nThe amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor oral dosage form (capsules):\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor thyroid cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—140 milligrams (mg) (one 80 mg and three 20 mg capsules) per day as a single dose. Your doctor may adjust the dose as needed.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor oral dosage form (tablets):\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor advanced kidney cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—60 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor advanced kidney cancer in combination with nivolumab:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—40 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor hepatocellular carcinoma:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—60 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor thyroid cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults and children 12 years of age and older—Dose is based on body surface area (BSA) and must be determined by your doctor.\r\n\u003cul\u003e\r\n \t\u003cli\u003eBSA of 1.2 meter squared (m2) or more—60 milligrams (mg) once a day. Your doctor may adjust your dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eBSA of less than 1.2 m2—40 mg once a day. Your doctor may adjust your dose as needed and tolerated.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eChildren younger than 12 years of age—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eMissed Dose\u003c\/h3\u003e\r\nIf you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.\r\n\r\nIf you miss a dose of this medicine and it is less than 12 hours until your next scheduled dose, skip the missed dose and take your next dose at the normal time. If you miss a dose and it is more than 12 hours until your next dose, take it as soon as possible and take your next dose at the normal time.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch3\u003eStorage\u003c\/h3\u003e\r\nStore the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.\r\n\r\nKeep out of the reach of children.\r\n\r\nDo not keep outdated medicine or medicine no longer needed.\r\n\r\nAsk your healthcare professional how you should dispose of any medicine you do not use.\r\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\r\nIt is very important that your doctor check your progress at regular visits to make sure this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.\r\n\r\nUsing this medicine while you are pregnant can harm your unborn baby. If you are a woman who can get pregnant, you doctor may do tests to make sure you are not pregnant before starting treatment. You should continue to use birth control during treatment with this medicine and for at least 4 months after the last dose to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away.\r\n\r\nCheck with your doctor right away if you have severe stomach pain, gagging, coughing, or choking when you eat or drink. These could be symptoms of a perforation (tear) or fistula (hole) in the bowel.\r\n\r\nThis medicine may increase your risk of bleeding. Tell your doctor right away if you cough up blood or have bleeding gums, difficulty with breathing or swallowing, dizziness, increased menstrual flow or vaginal bleeding, nosebleeds, prolonged bleeding from cuts, red or dark brown urine, or red or black, tarry stools. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers.\r\n\r\nThis medicine may increase your risk of developing blood clots. Check with your doctor right away if you have swelling and pain in your arms, legs, or stomach, chest pain, difficulty with breathing, loss of sensation, confusion, or problems with muscle control or speech.\r\n\r\nCheck with your doctor right away if you have chest pain or discomfort, nausea, pain or discomfort in your arms, jaw, back, or neck, sweating, or vomiting. These could be symptoms of a heart attack.\r\n\r\nMake sure any doctor or dentist who treats you knows that you are using this medicine. You may need to stop using this medicine at least 3 weeks before having surgery, including dental procedures. Wait for at least 2 weeks after major surgery, or until adequate wound healing before taking this medicine again.\r\n\r\nYour doctor will check your blood pressure on a regular basis while you are using this medicine. You might need to monitor your blood pressure at home. Tell your doctor right away if you have a severe headache, lightheadedness, or changes in your vision.\r\n\r\nTell your doctor right away if you have jaw tightness, swelling, numbness, pain, or a loose tooth. This could be symptoms of a severe jaw problem.\r\n\r\nThis medicine may cause a serious skin problem called hand-foot syndrome or palmar plantar erythrodysesthesia syndrome. Check with your doctor if you have a rash that does not go away or redness, pain, swelling, or blisters on the palms of your hands or soles of your feet.\r\n\r\nCheck with your doctor right away if you have dark urine, clay-colored stools, stomach pain, or yellow eyes or skin. These may be symptoms of a serious liver problem.\r\n\r\nThis medicine may cause adrenal gland problems. Check with your doctor right away if you have darkening of the skin, diarrhea, dizziness, fainting, loss of appetite, mental depression, nausea, skin rash, unusual tiredness or weakness, or vomiting.\r\n\r\nCheck with your doctor right away if you have a headache, seizures, confusion, blurred vision or other visual problems. These may be symptoms of a rare and serious brain condition called reversible posterior leukoencephalopathy syndrome.\r\n\r\nThis medicine may cause hypocalcemia (low calcium in the blood). Check with your doctor right away if you have confusion, difficulty in breathing, irregular heartbeats, mood or mental changes, muscle cramps in the hands, arms, feet, or face, numbness and tingling around the mouth, fingertips, or feet, seizures, stomach cramps, tremor, or trouble breathing.\r\n\r\nTalk with your doctor before using this medicine if you plan to have children. Some men and women who use this medicine have become infertile (unable to have children).\r\n\r\nDo not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (eg, St. John's wort) or vitamin supplements.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch2\u003eSide Effects\u003c\/h2\u003e\r\nAlong with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.\r\n\r\nCheck with your doctor immediately if any of the following side effects occur:\r\n\u003cdiv id=\"ad-mobile-top-container\"\u003e\u003c\/div\u003e\r\n\u003ch4\u003eMore common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBlurred vision\u003c\/li\u003e\r\n \t\u003cli\u003eburning, numbness, tingling, or painful sensations\u003c\/li\u003e\r\n \t\u003cli\u003econfusion\u003c\/li\u003e\r\n \t\u003cli\u003econstipation\u003c\/li\u003e\r\n \t\u003cli\u003edark urine\u003c\/li\u003e\r\n \t\u003cli\u003edarkening of the skin\u003c\/li\u003e\r\n \t\u003cli\u003edecreased urination\u003c\/li\u003e\r\n \t\u003cli\u003ediarrhea\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty with breathing or swallowing\u003c\/li\u003e\r\n \t\u003cli\u003edizziness\u003c\/li\u003e\r\n \t\u003cli\u003edry mouth\u003c\/li\u003e\r\n \t\u003cli\u003edry skin and hair\u003c\/li\u003e\r\n \t\u003cli\u003efainting\u003c\/li\u003e\r\n \t\u003cli\u003efeeling cold\u003c\/li\u003e\r\n \t\u003cli\u003ehair loss\u003c\/li\u003e\r\n \t\u003cli\u003eheadache\u003c\/li\u003e\r\n \t\u003cli\u003ehoarseness or husky voice\u003c\/li\u003e\r\n \t\u003cli\u003eincrease in heart rate\u003c\/li\u003e\r\n \t\u003cli\u003elightheadedness\u003c\/li\u003e\r\n \t\u003cli\u003eloss of appetite\u003c\/li\u003e\r\n \t\u003cli\u003emental depression\u003c\/li\u003e\r\n \t\u003cli\u003emuscle cramps, spasms, and stiffness\u003c\/li\u003e\r\n \t\u003cli\u003enausea or vomiting\u003c\/li\u003e\r\n \t\u003cli\u003enervousness\u003c\/li\u003e\r\n \t\u003cli\u003epain in the chest, groin, or legs, especially the calves\u003c\/li\u003e\r\n \t\u003cli\u003epounding in the ears\u003c\/li\u003e\r\n \t\u003cli\u003erapid breathing\u003c\/li\u003e\r\n \t\u003cli\u003eredness, swelling, or pain of the skin\u003c\/li\u003e\r\n \t\u003cli\u003escaling of the skin on the hands and feet\u003c\/li\u003e\r\n \t\u003cli\u003esevere, sudden headache\u003c\/li\u003e\r\n \t\u003cli\u003eskin rash or ulcers\u003c\/li\u003e\r\n \t\u003cli\u003eslow or fast heartbeat\u003c\/li\u003e\r\n \t\u003cli\u003eslurred speech\u003c\/li\u003e\r\n \t\u003cli\u003estomach pain\u003c\/li\u003e\r\n \t\u003cli\u003esudden loss of coordination\u003c\/li\u003e\r\n \t\u003cli\u003esudden, severe weakness or numbness in the arm or leg\u003c\/li\u003e\r\n \t\u003cli\u003esunken eyes\u003c\/li\u003e\r\n \t\u003cli\u003ethirst\u003c\/li\u003e\r\n \t\u003cli\u003eunsteadiness or awkwardness\u003c\/li\u003e\r\n \t\u003cli\u003eunusual tiredness or weakness\u003c\/li\u003e\r\n \t\u003cli\u003evision changes\u003c\/li\u003e\r\n \t\u003cli\u003eweakness in the arms, hands, legs, or feet\u003c\/li\u003e\r\n \t\u003cli\u003eweight gain\u003c\/li\u003e\r\n \t\u003cli\u003ewrinkled skin\u003c\/li\u003e\r\n \t\u003cli\u003eyellow eyes or skin\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003ch4\u003eLess common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBleeding gums\u003c\/li\u003e\r\n \t\u003cli\u003ebloody, black, or tarry stools\u003c\/li\u003e\r\n \t\u003cli\u003ecoughing up blood\u003c\/li\u003e\r\n \t\u003cli\u003eheartburn\u003c\/li\u003e\r\n \t\u003cli\u003eheavy jaw feeling\u003c\/li\u003e\r\n \t\u003cli\u003eincreased menstrual flow or vaginal bleeding\u003c\/li\u003e\r\n \t\u003cli\u003eindigestion\u003c\/li\u003e\r\n \t\u003cli\u003eloosening of a tooth\u003c\/li\u003e\r\n \t\u003cli\u003emood or mental changes\u003c\/li\u003e\r\n \t\u003cli\u003emuscle cramps in the hands, arms, feet, legs, or face\u003c\/li\u003e\r\n \t\u003cli\u003enosebleeds\u003c\/li\u003e\r\n \t\u003cli\u003enumbness and tingling around the mouth, fingertips, or feet\u003c\/li\u003e\r\n \t\u003cli\u003epain, swelling, or numbness in the mouth or jaw\u003c\/li\u003e\r\n \t\u003cli\u003eparalysis\u003c\/li\u003e\r\n \t\u003cli\u003eprolonged bleeding from cuts\u003c\/li\u003e\r\n \t\u003cli\u003ered or dark brown urine\u003c\/li\u003e\r\n \t\u003cli\u003eseizures\u003c\/li\u003e\r\n \t\u003cli\u003esevere stomach pain, cramping, or burning\u003c\/li\u003e\r\n \t\u003cli\u003etremor\u003c\/li\u003e\r\n \t\u003cli\u003etrouble breathing\u003c\/li\u003e\r\n \t\u003cli\u003evomiting of material that looks like coffee grounds, severe and continuing\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003ch4\u003eRare\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eDisturbed color perception\u003c\/li\u003e\r\n \t\u003cli\u003edouble vision\u003c\/li\u003e\r\n \t\u003cli\u003ehalos around lights\u003c\/li\u003e\r\n \t\u003cli\u003enight blindness\u003c\/li\u003e\r\n \t\u003cli\u003eoverbright appearance of lights\u003c\/li\u003e\r\n \t\u003cli\u003etunnel vision\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\nSome side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:\r\n\u003ch4\u003eMore common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBelching\u003c\/li\u003e\r\n \t\u003cli\u003ebleeding after defecation\u003c\/li\u003e\r\n \t\u003cli\u003echange in taste\u003c\/li\u003e\r\n \t\u003cli\u003echanges in hair color\u003c\/li\u003e\r\n \t\u003cli\u003edecreased appetite\u003c\/li\u003e\r\n \t\u003cli\u003edecreased weight\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty having a bowel movement\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty with moving\u003c\/li\u003e\r\n \t\u003cli\u003efear\u003c\/li\u003e\r\n \t\u003cli\u003elack or loss of strength\u003c\/li\u003e\r\n \t\u003cli\u003eloss of taste\u003c\/li\u003e\r\n \t\u003cli\u003emuscle pain\u003c\/li\u003e\r\n \t\u003cli\u003epain in the joints\u003c\/li\u003e\r\n \t\u003cli\u003erash\u003c\/li\u003e\r\n \t\u003cli\u003esore throat\u003c\/li\u003e\r\n \t\u003cli\u003estomach discomfort, upset, or pain\u003c\/li\u003e\r\n \t\u003cli\u003eswelling or inflammation of the mouth\u003c\/li\u003e\r\n \t\u003cli\u003euncomfortable swelling around the anus\u003c\/li\u003e\r\n \t\u003cli\u003evoice changes\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947150379,"sku":"RL1420230901445","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1950.jpg?v=1787022087"},{"product_id":"soranni-sorafenib-200mg-2","title":"Soranni (Sorafenib)","description":"\u003cstrong\u003eIndications\u003c\/strong\u003e\r\n\r\nIncluding: unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and local recovery that is refractory to radioactive iodine therapy\r\n\r\nHair or metastasis, and advanced differentiated thyroid cancer.\r\n\r\n\u003cstrong\u003eDose and administration method\u003c\/strong\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eMethod of administration\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e400mg (2 tablets) orally, twice a day, on an empty stomach.\u003c\/li\u003e\r\n \t\u003cli\u003eTo deal with suspected adverse drug reactions, treatment may need to be interrupted and\/or dose reduced. The dose can be reduced To 400mg once a day or to 400mg, once every other day.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"2\"\u003e\r\n \t\u003cli\u003eDosage specifications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTablets, 200mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"3\"\u003e\r\n \t\u003cli\u003eContraindications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePeople who are known to be allergic to sorafenib or any other components of the drug should not use sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eIn patients with squamous cell lung cancer, sorafenib is contraindicated in combination with carboplatin and paclitaxel.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eWarnings and Precautions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMyocardial ischemia and\/or infarction: consider temporarily or permanently discontinuing sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eBleeding: If bleeding requires medical intervention, consider discontinuing sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension: 6 weeks before treatment, regularly monitor blood pressure every week. Follow-up treatment should also be monitored regularly.\u003c\/li\u003e\r\n \t\u003cli\u003eSkin toxicity: Interrupt and\/or reduce the dose. Severe or persistent skin toxicity, or pregnant Stop taking the medication when you suspect Stevens-John syndrome and toxic epidermal necrolysis.\u003c\/li\u003e\r\n \t\u003cli\u003eGastrointestinal perforation: stop taking sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eProlonged QT interval: Patients with high risk of ventricular arrhythmia regularly monitor ECG and electrolyte levels.\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-induced hepatotoxicity: monitor liver function regularly; stop if there is an unexplained rise in transaminase Stop taking medicine.\u003c\/li\u003e\r\n \t\u003cli\u003eEmbryo toxicity: It is recommended that women of childbearing age avoid pregnancy when taking the drug.\u003c\/li\u003e\r\n \t\u003cli\u003eThyroid-stimulating hormone (TSH) damage in differentiated thyroid cancer (DTC): monitor TSH once a month,\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n(Please read this notice carefully and take the medicine according to this notice or under the guidance of a doctor)\r\n\u003cul\u003e\r\n \t\u003cli\u003eThyroid replacement therapy is suitable for patients with thyroid cancer.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdverse reactions\u003c\/strong\u003e\r\n\r\nThe most common adverse reactions related to sorafenib (≥20%): diarrhea, fatigue, infection, baldness, Hand and foot skin reactions, rash, weight loss, anorexia, nausea, gastrointestinal pain and abdominal pain, high blood pressure and blood.\r\n\r\n\u003cstrong\u003estorage method\u003c\/strong\u003e\r\n\r\nShading, cool and dry place","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948493867,"sku":"RL1420230901102","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655894917-557e1a1ef535bfa.png?v=1787022116"},{"product_id":"generic-larotrectinib-lucilaro","title":"PRASEDX (Pralsetinib)","description":"\u003ch2\u003eAbout  Pralsetinib\u003c\/h2\u003e\u003cp\u003ePralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.\u003c\/p\u003e\u003cp\u003ePralsetinib is a medication approved\u003csup id=\"cite_ref-10\" class=\"reference\"\u003e\u003c\/sup\u003e for RET mutation-positive medullary thyroid cancer (MTC)  and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy.\u003c\/p\u003e\u003cp\u003ePralsetinib is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) .\u003csup id=\"cite_ref-FDA_pralsetinib_12-4\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003eNon-Small Cell Lung Cancer\u003c\/h2\u003e\u003cp\u003eIndicated for metastatic rearranged during transfection (RET) gene-positive non-small cell lung cancer (NSCLC)\u003c\/p\u003e\u003cp\u003e400 mg PO qDay on an empty stomach\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eMedullary Thyroid Cancer\u003c\/h2\u003e\u003cp\u003eIndication was withdrawn in the U.S. by manufacturer on July 10, 2023\u003c\/p\u003e\u003cp\u003eThe decision was made to remove the indication after the confirmatory trial could not fulfill the postmarketing requirement\u003c\/p\u003e\u003ch2\u003eThyroid Cancer\u003c\/h2\u003e\u003cp\u003eIndicated for advanced or metastatic RET-fusion positive thyroid cancer in adults who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate)\u003c\/p\u003e\u003cp\u003e400 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\u003ch3\u003eDosage modifications for adverse reactions\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 300 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird dose reduction: 100 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eInterstitial lung disease (ILD)\/pneumonitis\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 1 or 2: Withhold until resolution; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 or recurrent ILD\/pneumonitis: Permanent discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHypertension\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold for persistent Grade 3 hypertension despite optimal antihypertensive therapy; resume at reduced dose once hypertension controlled\u003c\/li\u003e\n\u003cli\u003eGrade 4: Discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHepatoxicity\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold and monitor AST\/ALT once weekly until resolution to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eIf Grade ≥3 hepatotoxicity recurs, discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHemorrhagic events\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until recovery to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eDiscontinue for severe or life-threatening hemorrhagic events\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eOther adverse reactions\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until recovery to Grade ≤2; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrent Grade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eStrong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003e\n\u003ch4\u003eDosage modification if unable to avoid combined P-gp and strong CYP3A4 inhibitors\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eIf current pralsetinib dose is 300 or 400 mg qDay, reduce to 200 mg qDay\u003c\/li\u003e\n\u003cli\u003eIf current pralsetinib dose is 200 mg qDay, reduce to 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eAfter inhibitor has been discontinued for 3-5 elimination half-lives, resume at dose taken before initiating combined P-gp and strong CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eStrong CYP3A4 inducers\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer\u003c\/li\u003e\n\u003cli\u003eAfter inducer has been discontinued for at least 14 days, resume pralsetinib at dose taken before initiating strong CYP3A inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eRenal impairment\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;15 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHepatic impairment\u003c\/h3\u003e\u003cul\u003e\u003cli\u003eMild (total bilirubin less than or equal to ULN and AST \u0026gt; ULN or total bilirubin \u0026gt; 1 to 1.5 × ULN and any AST), moderate (total bilirubin \u0026gt; 1.5 to 3 × ULN and any AST) or severe (total bilirubin \u0026gt; 3 × ULN and any AST): No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949837355,"sku":"RL2820240816720","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-08-1279.jpg?v=1787022138"},{"product_id":"generic-crizotinib-lucicriz","title":"LENVIDX-4 (Lenvatinib)","description":"\u003ch3\u003eAbout Lenvatinib\u003c\/h3\u003e\u003cp\u003eLenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\u003c\/p\u003e\u003cp\u003e24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_everolimus\"\u003eCombination therapy with everolimus\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\n\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\n\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_pembrolizumab\"\u003eCombination therapy with pembrolizumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\n\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Dose_based_on_actual_body_weight\"\u003eDose based on actual body weight\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Endometrial_Cancer\"\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\u003c\/p\u003e\u003cp\u003e20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to pembrolizumab prescribing information for recommended dosing information\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"DTC_dose_reductions\"\u003eDTC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"RCC_or_endometrial_carcinoma_dose_reductions\"\u003eRCC or endometrial carcinoma dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_everolimus_in_RCC\"\u003eDose modification of everolimus in RCC\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\n\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_pembrolizumab_in_endometrial_carcinoma\"\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\n\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\n\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"HCC_dose_reductions\"\u003eHCC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"First_occurrence\"\u003eFirst occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Second_occurrence\"\u003eSecond occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Third_occurrence\"\u003eThird occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hypertension\"\u003eHypertension\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Cardiac_dysfunction\"\u003eCardiac dysfunction\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Arterial_thrombotic_event\"\u003eArterial thrombotic event\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Proteinuria\"\u003eProteinuria\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"GI_toxicity\"\u003eGI toxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_failure_or_impairment\"\u003eRenal failure or impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Reversible_posterior_leukoencephalopathy_syndrome_RPLS\"\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_CrCl_30_mLmin\"\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_Child-Pugh_C\"\u003eSevere (Child-Pugh C)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949902891,"sku":"RL3020241018","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-0942-jpg.webp?v=1787022139"},{"product_id":"generic-fionernone-lucifine","title":"LENVIDX-10 (Lenvatinib)","description":"\u003ch3\u003e\u003cspan id=\"About_Lenvatinib\"\u003eAbout Lenvatinib\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eLenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\u003c\/p\u003e\u003cp\u003e24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_everolimus\"\u003eCombination therapy with everolimus\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\n\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\n\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_pembrolizumab\"\u003eCombination therapy with pembrolizumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\n\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Dose_based_on_actual_body_weight\"\u003eDose based on actual body weight\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Endometrial_Cancer\"\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\u003c\/p\u003e\u003cp\u003e20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to pembrolizumab prescribing information for recommended dosing information\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"DTC_dose_reductions\"\u003eDTC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"RCC_or_endometrial_carcinoma_dose_reductions\"\u003eRCC or endometrial carcinoma dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_everolimus_in_RCC\"\u003eDose modification of everolimus in RCC\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\n\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_pembrolizumab_in_endometrial_carcinoma\"\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\n\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\n\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"HCC_dose_reductions\"\u003eHCC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"First_occurrence\"\u003eFirst occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Second_occurrence\"\u003eSecond occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Third_occurrence\"\u003eThird occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hypertension\"\u003eHypertension\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Cardiac_dysfunction\"\u003eCardiac dysfunction\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Arterial_thrombotic_event\"\u003eArterial thrombotic event\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Proteinuria\"\u003eProteinuria\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"GI_toxicity\"\u003eGI toxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_failure_or_impairment\"\u003eRenal failure or impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Reversible_posterior_leukoencephalopathy_syndrome_RPLS\"\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_CrCl_30_mLmin\"\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_Child-Pugh_C\"\u003eSevere (Child-Pugh C)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949968427,"sku":"RL3020241018","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-0972-jpg.webp?v=1787022141"},{"product_id":"generic-cabozantinib-cabodx-60","title":"CABODX 60 (Cabozantinib)","description":"\u003cp\u003eCabozantinib is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Medullary_Thyroid_Cancer\"\u003eMedullary Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eCapsule only\u003c\/p\u003e\u003cp\u003eIndicated for treatment of progressive, metastatic medullary thyroid cancer (MTC)\u003c\/p\u003e\u003cp\u003e140 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Combination_with_nivolumab\"\u003eCombination with nivolumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with nivolumab for first-line treatment of advanced renal cell carcinoma (RCC)\u003c\/li\u003e\n\u003cli\u003eCabozantinib 40 mg PO qDay PLUS nivolumab 240 mg IV q2Weeks or 480 mg IV q4Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eNivolumab only: Continue for up to 2 years\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Single_agent\"\u003eSingle agent\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for advanced RC\u003c\/li\u003e\n\u003cli\u003e60 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003cp\u003eIndicated for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib\u003c\/p\u003e\u003cp\u003e60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced or metastatic differentiated thyroid cancer (DTC) in adults who have progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible\u003c\/p\u003e\u003cp\u003eBSA \u0026gt;1.2 m\u003csup\u003e2\u003c\/sup\u003e: 60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_reductions_Cabometyx\"\u003eDosage reductions (Cabometyx)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Monotherapy_with_BSA_12_m2\"\u003eMonotherapy with BSA \u0026gt;1.2 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg qDay: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg qDay: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"In_combination_with_nivolumab\"\u003eIn combination with nivolumab\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO every other day\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg every other day: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg every other day: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_Grade_1_or_until_complete_resolution\"\u003eWithhold dose until Grade ≤1 or until complete resolution\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 diarrhea\u003c\/li\u003e\n\u003cli\u003eGrade 3 or intolerable grade 2 palmar-plantar erythrodysesthesia\u003c\/li\u003e\n\u003cli\u003eGrade 2 or 3 proteinuria\u003c\/li\u003e\n\u003cli\u003eAny grade osteonecrosis of jaw (ONJ)\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 or intolerable grade 2 other adverse reactions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_Grade_1\"\u003eWithhold dose until Grade ≤1\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eConsider corticosteroid therapy if withheld or discontinued when administered in combination with nivolumab\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;3x ULN but ≤10x ULN with concurrent total bilirubin [TB] \u0026lt;2x ULN\u003c\/li\u003e\n\u003cli\u003eAfter recovery, consider rechallenge with one or both of Cabometyx and nivolumab\u003c\/li\u003e\n\u003cli\u003eIf rechallenging with nivolumab with or without Cabometyx, refer to nivolumab prescribing information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_adequately_controlled_at_Grade_2\"\u003eWithhold dose until adequately controlled at Grade ≤2\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 hypertension and hypertensive crisis\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Permanently_discontinue\"\u003ePermanently discontinue\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrades 3 or 4 hemorrhage\u003c\/li\u003e\n\u003cli\u003eAny grade gastrointestinal perforation\u003c\/li\u003e\n\u003cli\u003eGrade 4 fistula\u003c\/li\u003e\n\u003cli\u003eAny grade acute myocardial infarction\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 cerebral infarction\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 arterial thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 venous thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 hypertension or uncontrolled hypertensive crisis\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome\u003c\/li\u003e\n\u003cli\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;10x ULN or \u0026gt;3x ULN with concurrent TB ≥2x ULN; permanently discontinue both nivolumab and Cabometyx\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"CYP3A4_inhibitors\"\u003eCYP3A4 inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration with strong CYP3A4 inhibitors\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 40 mg\/day (eg, from 140 mg to 100 mg qDay)\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 20 mg\/day (eg, from 60 mg to 40 mg qDay)\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inhibitor discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"CYP3A4_inducers\"\u003eCYP3A4 inducers\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration of strong CYP3A4 inducers\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inducer required, increase dose by 40 mg\/day (eg, from 140 mg to 180 mg qDay); do not exceed 180 mg\/day\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inducer required, increase dose by 20 mg\/day (eg, from 60 mg to 80 mg qDay); do not exceed 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inducer discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet1\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): Reduce starting dose to 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet2\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): Reduce starting dose to 40 mg\/day\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): No experience\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797951672363,"sku":"RL1720231021","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-10-3072.jpg?v=1787022157"},{"product_id":"generic-cabozantinib-cabodx-80","title":"CABODX 80 (Cabozantinib)","description":"\u003cp\u003eCabozantinib is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Medullary_Thyroid_Cancer\"\u003eMedullary Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eCapsule only\u003c\/p\u003e\u003cp\u003eIndicated for treatment of progressive, metastatic medullary thyroid cancer (MTC)\u003c\/p\u003e\u003cp\u003e140 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Combination_with_nivolumab\"\u003eCombination with nivolumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with nivolumab for first-line treatment of advanced renal cell carcinoma (RCC)\u003c\/li\u003e\n\u003cli\u003eCabozantinib 40 mg PO qDay PLUS nivolumab 240 mg IV q2Weeks or 480 mg IV q4Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eNivolumab only: Continue for up to 2 years\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Single_agent\"\u003eSingle agent\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for advanced RC\u003c\/li\u003e\n\u003cli\u003e60 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003cp\u003eIndicated for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib\u003c\/p\u003e\u003cp\u003e60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced or metastatic differentiated thyroid cancer (DTC) in adults who have progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible\u003c\/p\u003e\u003cp\u003eBSA \u0026gt;1.2 m\u003csup\u003e2\u003c\/sup\u003e: 60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_reductions_Cabometyx\"\u003eDosage reductions (Cabometyx)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Monotherapy_with_BSA_12_m2\"\u003eMonotherapy with BSA \u0026gt;1.2 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg qDay: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg qDay: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"In_combination_with_nivolumab\"\u003eIn combination with nivolumab\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO every other day\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg every other day: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg every other day: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_Grade_1_or_until_complete_resolution\"\u003eWithhold dose until Grade ≤1 or until complete resolution\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 diarrhea\u003c\/li\u003e\n\u003cli\u003eGrade 3 or intolerable grade 2 palmar-plantar erythrodysesthesia\u003c\/li\u003e\n\u003cli\u003eGrade 2 or 3 proteinuria\u003c\/li\u003e\n\u003cli\u003eAny grade osteonecrosis of jaw (ONJ)\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 or intolerable grade 2 other adverse reactions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_Grade_1\"\u003eWithhold dose until Grade ≤1\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eConsider corticosteroid therapy if withheld or discontinued when administered in combination with nivolumab\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;3x ULN but ≤10x ULN with concurrent total bilirubin [TB] \u0026lt;2x ULN\u003c\/li\u003e\n\u003cli\u003eAfter recovery, consider rechallenge with one or both of Cabometyx and nivolumab\u003c\/li\u003e\n\u003cli\u003eIf rechallenging with nivolumab with or without Cabometyx, refer to nivolumab prescribing information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_adequately_controlled_at_Grade_2\"\u003eWithhold dose until adequately controlled at Grade ≤2\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 hypertension and hypertensive crisis\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Permanently_discontinue\"\u003ePermanently discontinue\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrades 3 or 4 hemorrhage\u003c\/li\u003e\n\u003cli\u003eAny grade gastrointestinal perforation\u003c\/li\u003e\n\u003cli\u003eGrade 4 fistula\u003c\/li\u003e\n\u003cli\u003eAny grade acute myocardial infarction\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 cerebral infarction\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 arterial thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 venous thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 hypertension or uncontrolled hypertensive crisis\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome\u003c\/li\u003e\n\u003cli\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;10x ULN or \u0026gt;3x ULN with concurrent TB ≥2x ULN; permanently discontinue both nivolumab and Cabometyx\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"CYP3A4_inhibitors\"\u003eCYP3A4 inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration with strong CYP3A4 inhibitors\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 40 mg\/day (eg, from 140 mg to 100 mg qDay)\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 20 mg\/day (eg, from 60 mg to 40 mg qDay)\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inhibitor discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"CYP3A4_inducers\"\u003eCYP3A4 inducers\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration of strong CYP3A4 inducers\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inducer required, increase dose by 40 mg\/day (eg, from 140 mg to 180 mg qDay); do not exceed 180 mg\/day\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inducer required, increase dose by 20 mg\/day (eg, from 60 mg to 80 mg qDay); do not exceed 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inducer discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet1\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): Reduce starting dose to 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet2\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): Reduce starting dose to 40 mg\/day\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): No experience\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797951737899,"sku":"RL1720231021","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-10-3044.jpg?v=1787022158"},{"product_id":"generic-entrectinib-entredx-200","title":"ENTREDX 200 (entrectinib)","description":"\u003cdiv class=\"collapse-more\"\u003e\u003ch3\u003eNon-small Cell Lung Cancer\u003c\/h3\u003e\u003c\/div\u003e\u003cp\u003eIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are ROS1-positive\u003c\/p\u003e\u003cp\u003e600 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eNeurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and progressed following treatment or have no satisfactory alternative therapy\u003c\/p\u003e\u003cp\u003e600 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 400 mg qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if toxicities persist or recur following 2 dose reductions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCongestive heart failure\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2 or 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCentral nervous system effects\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIntolerable Grade 2: Withhold until recovered to Grade ≤1; resume at reduced dose, as clinically appropriate\u003c\/li\u003e\n\u003cli\u003eGrade 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3\u003cul\u003e\n\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduced dose;\u003c\/li\u003e\n\u003cli\u003eIf resolution occurs within 4 weeks, resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf adverse reaction persists after 4 weeks, permanently discontinue\u003c\/li\u003e\n\u003cli\u003eFor recurrent Grade 3 events that resolve within 4 weeks, resume at a reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduce dose;\u003c\/li\u003e\n\u003cli\u003eIf adverse reaction does not resolve within 4 weeks or Grade 4 events recurs, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eElevated ALT or AST\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eALT or AST \u0026gt;3x ULN with concurrent total bilirubin \u0026gt;1.5x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHyperuricemia\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSymptomatic or Grade 4: Initiate urate-lowering therapy; withhold until improvement of signs or symptoms; resume at same or reduced dose\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eQTc prolongation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eQTc \u0026gt;500 ms\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until QTc interval recovers to baseline\u003c\/li\u003e\n\u003cli\u003eResume at same dose if causes of QT prolongation are identified and corrected\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose if other causes of QT prolongation are not identified\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eLife-threatening arrhythmia\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eTorsade de pointes; polymorphic ventricular tachycardia; signs\/symptoms of serious arrhythmia: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eVision disorders\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade ≥2: Withhold until improvement or stabilization; resume at same dose or reduced dose, as clinically appropriate\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eAnemia or neutropenia\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until recovery to Grade≤2; resume at same or reduced dose, as clinically appropriate\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eOther clinically relevant adverse reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eGrade 3 or 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until adverse reaction resolves to Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at same or reduced dose if resolved within 4 weeks\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if adverse reaction does not resolve within 4 weeks or Grade 4 events recurs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eCoadministration of moderate and strong CYP3A inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIf coadministration is unavoidable, reduce entrectinib dose as follows:\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eModerate CYP3A Inhibitors: 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eStrong CYP3A Inhibitors: 100 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eAfter discontinuation of strong or moderate CYP3A inhibitor for 3-5 elimination half-lives, resume entrectinib dose taken prior to initiating the CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30 to \u0026lt;90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin ≤1.5x ULN): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe (total bilirubin \u0026gt;1.5x ULN): Not studied; consider risk-benefit profile prior to determining whether to administer therapy to patients with moderate to severe hepatic impairment; monitor for adverse reactions in patients with hepatic impairment more frequently; these patients may be at increased risk for adverse reactions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNSCLC: Presence of ROS1 rearrangement\u003c\/li\u003e\n\u003cli\u003eLocally advanced or metastatic solid tumors: Presence of a NTRK gene fusion\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797951770667,"sku":"RL2020231212780","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1268.jpg?v=1787022160"},{"product_id":"generic-larotrectinib-larotreni-100","title":"Larotreni 100 (Larotrectinib)","description":"\u003cp\u003eLarotrectinib is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change. You might have larotrectinib for a solid cancer if: your cancer is locally advanced or advanced (metastatic) surgery to remove the cancer could cause severe health problems.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Solid_Tumors\"\u003eSolid Tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003e100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Body_Surface_Area_BSA_1_m2\"\u003eBody Surface Area (BSA) ≥1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797951836203,"sku":"RL2020231212933","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1469.jpg?v=1787022161"},{"product_id":"generic-larotrectinib-larodx-25","title":"LARODX 25 (Larotrectinib)","description":"\u003ch2\u003eLarotrectinib\u003c\/h2\u003e\u003cp\u003eLarotrectinib is a medication for the treatment of cancer.\u003csup id=\"cite_ref-Vitrakvi_AU_summary_4-0\" class=\"reference\"\u003e\u003c\/sup\u003eIt is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.\u003csup id=\"cite_ref-pmid30069765_7-0\" class=\"reference\"\u003e\u003c\/sup\u003e \u003c\/p\u003e\u003cp\u003eLarotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.\u003c\/p\u003e\u003cp\u003eLarotrectinib was the first drug to be specifically developed and approved to treat \u003ci\u003eany\u003c\/i\u003e cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is \"tissue agnostic\"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.\u003csup id=\"cite_ref-14\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003eADULT\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003eDosage Forms \u0026amp; Strengths\u003c\/h3\u003e\n\u003ch4\u003ecapsule\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eoral solution\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003eSolid Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003e100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eBody Surface Area (BSA) ≥1 m2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eGrade ≥3 adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modification\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inducers\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken prior to initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003ePEDIATRIC\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003eDosage Forms \u0026amp; Strengths\u003c\/h3\u003e\n\u003ch4\u003ecapsule\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eoral solution\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003eSolid Tumors\u003c\/h3\u003e\u003cp\u003endicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003eBody surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Pediatric Dosing \u0026amp; Uses\" data-text=\"Body surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003cp\u003eBSA ≥1 m\u003csup\u003e2\u003c\/sup\u003e: 100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eBSA \u0026lt;1 m2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Not to exceed 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID; remain on 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID even if BSA becomes \u0026gt;1 m\u003csup\u003e2\u003c\/sup\u003e during treatment\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eBSA ≥1 m2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eGrade ≥3 adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modificatio\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inducers\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797952950315,"sku":"RL2620240606","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-05-3027.jpg?v=1787022187"},{"product_id":"generic-larotrectinib-larodx-100","title":"LARODX 100 (Larotrectinib)","description":"\u003ch2\u003e\u003cspan id=\"Larotrectinib\"\u003eLarotrectinib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eLarotrectinib is a medication for the treatment of cancer.\u003csup id=\"cite_ref-Vitrakvi_AU_summary_4-0\" class=\"reference\"\u003e\u003c\/sup\u003eIt is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.\u003csup id=\"cite_ref-pmid30069765_7-0\" class=\"reference\"\u003e\u003c\/sup\u003e \u003c\/p\u003e\u003cp\u003eLarotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.\u003c\/p\u003e\u003cp\u003eLarotrectinib was the first drug to be specifically developed and approved to treat \u003ci\u003eany\u003c\/i\u003e cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is \"tissue agnostic\"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.\u003csup id=\"cite_ref-14\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"ADULT\"\u003eADULT\u003c\/span\u003e\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003e\u003cspan id=\"Dosage_Forms_Strengths\"\u003eDosage Forms \u0026amp; Strengths\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch4\u003e\u003cspan id=\"capsule\"\u003ecapsule\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003e\u003cspan id=\"oral_solution\"\u003eoral solution\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003e\u003cspan id=\"Solid_Tumors\"\u003eSolid Tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003e100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Body_Surface_Area_BSA_1_m2\"\u003eBody Surface Area (BSA) ≥1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Grade_3_adverse_reactions\"\u003eGrade ≥3 adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modification\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inhibitors\"\u003eStrong CYP3A4 inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inducers\"\u003eStrong CYP3A4 inducers\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken prior to initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Patient_selection\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"PEDIATRIC\"\u003ePEDIATRIC\u003c\/span\u003e\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003e\u003cspan id=\"Dosage_Forms_Strengths1\"\u003eDosage Forms \u0026amp; Strengths\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch4\u003e\u003cspan id=\"capsule1\"\u003ecapsule\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003e\u003cspan id=\"oral_solution1\"\u003eoral solution\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003e\u003cspan id=\"Solid_Tumors1\"\u003eSolid Tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003endicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003eBody surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Pediatric Dosing \u0026amp; Uses\" data-text=\"Body surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003cp\u003eBSA ≥1 m\u003csup\u003e2\u003c\/sup\u003e: 100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications1\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions1\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"BSA_1_m2\"\u003eBSA \u0026lt;1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Not to exceed 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID; remain on 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID even if BSA becomes \u0026gt;1 m\u003csup\u003e2\u003c\/sup\u003e during treatment\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003e\u003cspan id=\"BSA_1_m21\"\u003eBSA ≥1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Grade_3_adverse_reactions1\"\u003eGrade ≥3 adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modificatio\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inhibitors1\"\u003eStrong CYP3A4 inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inducers1\"\u003eStrong CYP3A4 inducers\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment1\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment1\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosing_Considerations1\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Patient_selection1\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797952983083,"sku":"RL2620240606","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-05-3069.jpg?v=1787022188"},{"product_id":"lucivande-vandetanib","title":"LuciVande 100 (Vandetanib)","description":"\u003cp\u003e\u003cstrong\u003eAbout Vandetanib \u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.\u003c\/p\u003e\u003ch3\u003eMedullary Thyroid Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e300 mg PO qDay with or without food\u003c\/p\u003e\u003cp\u003eContinued until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose Reduction\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade ≥3 toxicities: Reduce to 200 mg qDay; then further reduce to 100 mg qDay if necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eInterrupt therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eCorrected QT interval, Fridericia (QTcB) interval \u0026gt;500 msec: Resume at reduce dose once QTcF ≤450 msec\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 toxicity: Resume at reduced dose once toxicity resolves to Grade \u0026lt;1\u003c\/li\u003e\n\u003cli\u003eRecurrent toxicities: Reduce dose to 100 mg once toxicity resolves to Grade \u0026lt;1, if continued treatment is warranted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl ≥50 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (CrCl 30 to \u0026lt;50 mL\/min): Reduce starting dose to 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not recommended\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease requiring dialysis: Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child Pugh A): Dose adjustment not described in manufacturer's label\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe (Child-Pugh B or C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957996587,"sku":"RL362025060601","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0674.jpg?v=1787022294"},{"product_id":"lucivande-300-vandetanib","title":"LuciVande 300 (Vandetanib)","description":"\u003cp\u003e\u003cstrong\u003eAbout Vandetanib \u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Medullary_Thyroid_Cancer\"\u003eMedullary Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e300 mg PO qDay with or without food\u003c\/p\u003e\u003cp\u003eContinued until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dose_Reduction\"\u003eDose Reduction\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade ≥3 toxicities: Reduce to 200 mg qDay; then further reduce to 100 mg qDay if necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Interrupt_therapy\"\u003eInterrupt therapy\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eCorrected QT interval, Fridericia (QTcB) interval \u0026gt;500 msec: Resume at reduce dose once QTcF ≤450 msec\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 toxicity: Resume at reduced dose once toxicity resolves to Grade \u0026lt;1\u003c\/li\u003e\n\u003cli\u003eRecurrent toxicities: Reduce dose to 100 mg once toxicity resolves to Grade \u0026lt;1, if continued treatment is warranted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl ≥50 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (CrCl 30 to \u0026lt;50 mL\/min): Reduce starting dose to 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not recommended\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease requiring dialysis: Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child Pugh A): Dose adjustment not described in manufacturer's label\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe (Child-Pugh B or C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797958029355,"sku":"RL362025060602","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0687.jpg?v=1787022295"},{"product_id":"lenvaxen-10-lenvatinib-mesylate-inn-equivalent-to-lenvatinib-10-mg","title":"Lenvaxen 10 (Lenvatinib Mesylate INN equivalent to Lenvatinib 10 mg)","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-3 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eLenvaxen 10 is an oral targeted anticancer medicine containing Lenvatinib 10 mg, a tyrosine kinase inhibitor (TKI). It works by inhibiting signaling pathways involved in tumor growth and angiogenesis and is used in the treatment of certain cancers, including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in appropriate treatment settings.\u003c\/strong\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"z-0 flex min-h-[46px] justify-start\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1\"\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44890202406955,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Lenvaxen10.jpg?v=1787228317"},{"product_id":"selpacta-40-selpercatinib","title":"Selpacta 40 (Selpercatinib)","description":"\u003cp\u003e\u003cstrong\u003eSelpacta 40 (Selpercatinib)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003eselpercatinib\u003c\/strong\u003e\u003cspan\u003e, a selective RET kinase inhibitor that blocks abnormal RET signaling involved in cancer growth and progression. It is used for the treatment of certain \u003c\/span\u003e\u003cstrong\u003eRET fusion-positive or RET mutation-positive cancers\u003c\/strong\u003e\u003cspan\u003e, including specific cases of non-small cell lung cancer, thyroid cancer, and other advanced solid tumors. Selpacta 40 contains \u003c\/span\u003e\u003cstrong\u003e40 mg of selpercatinib\u003c\/strong\u003e\u003cspan\u003e and is supplied in a \u003c\/span\u003e\u003cstrong\u003e30-capsule pack\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44896169885739,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/selpacta-40-163.jpg?v=1787299455"},{"product_id":"selpacta-selpercatinib-inn","title":"SELPACTA (SELPERCATINIB INN)","description":"\u003cp\u003e\u003cstrong\u003eSELPACTA (Selpercatinib INN)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003eselpercatinib\u003c\/strong\u003e\u003cspan\u003e, a selective RET kinase inhibitor that blocks abnormal RET signaling involved in cancer cell growth and progression. It is used for certain \u003c\/span\u003e\u003cstrong\u003eRET fusion-positive or RET mutation-positive cancers\u003c\/strong\u003e\u003cspan\u003e, including specific cases of non-small cell lung cancer and thyroid cancer. SELPACTA is listed as an \u003c\/span\u003e\u003cstrong\u003eanti-cancer\u003c\/strong\u003e\u003cspan\u003e medicine and is supplied in a \u003c\/span\u003e\u003cstrong\u003e30-capsule pack\u003c\/strong\u003e\u003cspan\u003e. \u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44897031553067,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/selpacta.png?v=1787315256"},{"product_id":"selcaxen-40-mg-selpercatinib","title":"Selcaxen 40 mg (selpercatinib)","description":"\u003cp\u003e\u003cstrong\u003eSelcaxen 40 mg\u003c\/strong\u003e contains \u003cstrong\u003eselpercatinib\u003c\/strong\u003e, a targeted anticancer medicine that belongs to the \u003cstrong\u003eRET kinase inhibitor\u003c\/strong\u003e class. It works by blocking abnormal RET signaling that can promote cancer cell growth and spread. Selcaxen is used to treat certain \u003cstrong\u003eRET fusion-positive or RET-mutated cancers\u003c\/strong\u003e, including some forms of non-small cell lung cancer and thyroid cancer. It is an oral capsule and should be used under the supervision of an oncologist.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44898305835051,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Selcaxen-40.png?v=1787345383"},{"product_id":"lenvaxen-4-lenvatinib-mesylate-inn-equivalent-to-lenvatinib-4-mg","title":"Lenvaxen 4 (Lenvatinib Mesylate INN equivalent to Lenvatinib 4 mg)","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-3 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003eLenvaxen 4 is used for certain advanced cancers, including \u003cstrong\u003eradioactive-iodine-refractory differentiated thyroid cancer, advanced kidney cancer, unresectable liver cancer, and certain advanced endometrial cancers\u003c\/strong\u003e, depending on the treatment regimen and patient characteristics. Lenvatinib works by inhibiting several kinase pathways involved in tumor growth and blood-vessel formation. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eIt is a \u003cstrong\u003eprescription anticancer medicine\u003c\/strong\u003e and should be used under an oncologist's supervision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"z-0 flex min-h-[46px] justify-start\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1\"\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45023187304491,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Lenvaxen4.jpg?v=1787513147"}],"url":"https:\/\/xomeds.com\/collections\/thyroid-cancer.oembed","provider":"XOMEDS","version":"1.0","type":"link"}